Get the latest Science News and Discoveries

Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity

The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.

None

Get the Android app